Lysine specific demethylase 5B promises to be a new focus of cancer drug-resistance: combination therapy.
Drug resistance remains a major obstacle to the long-term efficacy of cancer therapy. Lysine specific demethylase 5B (KDM5B), an epigenetic regulator of H3K4 methylation, has emerged as an important modulator of therapeutic resistance across multiple tumor contexts. In this review, we systematically summarize the mecha...